Ceribell, Inc. ((CBLL)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ceribell’s latest earnings call painted a picture of a fast-growing medtech company balancing strong commercial momentum with rising costs and near-term uncertainties. Management stressed robust top-line expansion, high margins and a significantly larger addressable market, while also acknowledging higher operating expenses, tariff impacts and legal spending that will weigh on profitability in the short run.
Double-Digit Revenue Growth Underpins the Story
Ceribell delivered Q4 2025 revenue of $24.8 million, up 34% year over year, capping a full-year result of $89.1 million, up 36%. This level of sustained double-digit growth signals continued adoption of the company’s neurodiagnostic platform across hospitals and supports the bullish tone around its long-term opportunity.
Products and Subscriptions Both Firing
The revenue mix showed strength in both one-time systems and recurring fees, with Q4 products revenue at $18.8 million (+33%) and subscriptions at $6.0 million (+37%). For 2025 overall, products generated $67.3 million (+34%) and subscriptions $21.7 million (+41%), underscoring a healthy recurring base that can smooth volatility over time.
Premium Gross Margins Show Resilience
Gross margins remained a standout metric at 87% in Q4 and 88% for the full year, even with some tariff-related headwinds late in the year. Management guided to mid-80% gross margins in 2026 as it mitigates tariff impact and adjusts manufacturing, suggesting the business should retain a highly attractive economic profile.
Customer Count Climbs with Ample Runway
The company ended 2025 with 647 active accounts after adding 32 in Q4 and 118 across the year, indicating healthy traction in hospital adoption. Yet Ceribell estimates it has penetrated less than 4% of its $2.5 billion core seizure market, leaving substantial room for further installations and deeper utilization at existing sites.
Regulatory Wins Open New Clinical Doors
Ceribell scored a series of high-impact regulatory and market access wins, including FedRAMP High status that opens the door to 170 VA hospitals following a successful pilot. It also secured FDA clearance for neonatal and pediatric seizure detection, the first FDA-cleared delirium continuous monitoring algorithm and Breakthrough Device status for large-vessel-occlusion stroke monitoring.
Total Addressable Market Jumps Above $3.5 Billion
On the back of these new indications and clearances, management lifted its total addressable market estimate from roughly $2 billion to more than $3.5 billion. This expanded TAM reflects Ceribell’s move beyond adult seizure detection into pediatrics, delirium and stroke, framing a multi-year growth runway that extends well past current revenue levels.
Balance Sheet Supports Ongoing Investment
Ceribell closed 2025 with $159.3 million in cash, cash equivalents and marketable securities, giving it ample liquidity to fund growth initiatives. Management plans to selectively invest in R&D and commercial expansion, betting that today’s spending will translate into higher share of a much larger neurocritical care market.
2026 Guidance Signals Solid but Slower Growth
For 2026, the company guided revenue to $111–$115 million, implying 25%–29% growth on top of 2025’s 36% expansion. The outlook is framed as conservative, reflecting only modest near-term revenue contribution from new indications and leaving potential upside from additional account momentum and later-stage product ramps.
Operating Expenses Climb with Scale
Total operating expenses rose to $36.2 million in Q4 2025, up 24% year over year, and $136.7 million for the full year, up 42%. The increase was driven by commercial buildout, headcount growth and the added costs of being a public company, signaling a deliberate spend-now, harvest-later posture.
Net Loss Widens Despite Better Per-Share Results
Ceribell’s full-year net loss increased to $53.4 million in 2025 from $40.5 million in 2024, reflecting heavier investment and legal expenses. However, loss per share improved to $1.46 from $3.39, helped by a larger share base, while Q4 net loss ticked up modestly to $13.5 million from $12.6 million.
Tariffs Create Margin Noise but Limited Structural Damage
Gross margin dipped slightly to 87% in Q4 from 88% previously due to partial-quarter impact from inventory subject to higher tariffs on China-origin products. Management’s 2026 margin guide excludes any further policy shocks, and it expects mitigation actions and manufacturing changes to stabilize margins in the mid-80% range.
New Indications to Build Gradually
While the neonatal and pediatric indication is slated for a full commercial launch in Q2 2026, the company expects only modest revenue contribution this year. Multi-month sales cycles and the need for departmental and committee approvals in hospitals mean that the real revenue lift is more likely to show up from 2027 onward.
Litigation Adds Near-Term Cost Overhang
Ongoing ITC patent litigation with Natus remains in the discovery phase and is expected to inflate legal and G&A expenses, especially in the first half of 2026. Investors should therefore anticipate elevated non-operating costs in the near term even as core demand trends and account adds remain supportive.
Conservative Guidance Reflects Execution and Timing Risks
Management emphasized a cautious guidance stance, despite the larger TAM and recent product wins, to account for potential execution risk around broader system-wide and pediatric deployments. This conservative posture aims to set achievable expectations while the company works through longer adoption timelines in new clinical settings.
R&D and Equity Compensation to Pressure OpEx
Looking ahead, R&D spending is expected to grow faster than other functions in 2026 as Ceribell continues to invest in its technology roadmap. Non-cash stock-based compensation is also set to rise with public-company compensation practices, further pressuring operating expenses in the near term before revenue scales.
Guidance Points to Continued Growth and Long-Term Upside
Ceribell’s 2026 guidance calls for $111–$115 million in revenue, 25%–29% growth on 2025’s $89.1 million base, alongside mid-80% gross margins and a plan to exceed the 118 accounts added last year. With less than 4% penetration of a $2.5 billion core seizure market, a ~$3.5 billion TAM, a strong cash position around $159 million and a mix of product and subscription revenues, the company aims for higher utilization and eventual cash-flow breakeven despite expected variability in OpEx and legal costs.
Ceribell’s earnings call presented a compelling growth narrative backed by strong revenue gains, premium margins and a rapidly expanding market opportunity. While rising expenses, tariffs and litigation temper near-term profitability, management’s cautious guidance and ample cash suggest the company is positioning itself to convert today’s investments into long-term value for shareholders.